We hope the new year is off to a great start for you! The Myasthenia Alliance Australia (MAA) is sharing the attached information with you about the current opportunity to make a personal submission to the Pharmaceutical Benefits Advisory Committee (PBAC) about a new treatment called Ultomiris (Ravulizumab).
Please read this in addition to the information we shared in December, which can also be accessed here: https://myastheniaalliance.
A reminder that the deadline for submissions is Wednesday, 31 January 2024.
The Consumer Submission can be downloaded as a PDF from here:
The Consumer Submission can be downloaded as a Word document from here:
PBAC Consumer Submission for Ravulizumab – January 2024 (Part 2)
PBAC Consumer Submission for Ravulizumab – January 2024 (Part 2)
The Government’s Consumer Medicine Information (CMI) about Ultomiris (Ravulizumab) can be accessed via this link.
Kind regards,
The MAA Board